<sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib

<sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib

Background: The tyrosine kinase inhibitor (TKI) Lenvatinib represents one of the most effective therapeutic options in patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC). We aimed to assess the role of 2-deoxy-2-[<sup>18</sup>F] fluoro-D-glucose positron...

Full description

Bibliographic Details
Main Authors: Freba Ahmaddy, Caroline Burgard, Leonie Beyer, Viktoria Koehler, Peter Bartenstein, Matthias P. Fabritius, Thomas Geyer, Vera Wenter, Harun Ilhan, Christine Spitzweg, Andrei Todica
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
differentiated thyroid cancer
radioiodine refractory
Lenvatinib
<sup>18</sup>F-FDG-PET/CT
Online Access:https://www.mdpi.com/2072-6694/13/2/317

Internet

https://www.mdpi.com/2072-6694/13/2/317

Similar Items